Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

Abstract Background Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second-generation ALK TKI have demonstrated superiority compared to the fi...

Full description

Bibliographic Details
Main Authors: Petros Christopoulos, Farastuk Bozorgmehr, Lena Brückner, Inn Chung, Johannes Krisam, Marc A. Schneider, Albrecht Stenzinger, Regina Eickhoff, Daniel W. Mueller, Michael Thomas
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
Anaplastic lymphoma kinase
ALK+ NSCLC
Tyrosine kinase inhibitors (TKI)
Brigatinib
Resistance mutations
Online Access:https://doi.org/10.1186/s12885-021-08460-w

Internet

https://doi.org/10.1186/s12885-021-08460-w

Similar Items